Compare SURG & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | KTTA |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 16.2M |
| IPO Year | N/A | N/A |
| Metric | SURG | KTTA |
|---|---|---|
| Price | $0.88 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.75 | $3.00 |
| AVG Volume (30 Days) | ★ 157.4K | 139.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.78 | N/A |
| Revenue Next Year | $113.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $0.28 |
| 52 Week High | $3.47 | $2.34 |
| Indicator | SURG | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 51.11 |
| Support Level | $0.75 | $0.78 |
| Resistance Level | $0.95 | $0.88 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 64.89 | 62.10 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).